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Abstract
Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on
treatment outcomes with 177Lu-Dotatate.
Methods In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were
randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60
mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden,
ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding
95% CIs were estimated using Cox regression.
Results Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low (<
25%), moderate (25–50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR
0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-
Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P =
0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved
PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline
liver tumour burden.
Conclusions 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with ad-
vanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion.
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Introduction
The liver is the dominant site of metastatic disease amongst
patients with stage IV well-differentiated neuroendocrine tu-
mours (NET) [1]. High liver tumour burden has been shown
to be a poor prognostic factor in multiple studies [2–8]. In the
phase 3 PROMID study (which randomised patients with
midgut NET to octreotide long-acting release [LAR] versus
placebo), liver tumour burden > 10% was associated with a
hazard ratio (HR) for progression of 2.63 onmultivariate anal-
ysis [2]. Another prognostic factor is serum alkaline phospha-
tase (ALP) [9–13], which may be elevated with extensive liver
involvement and bone metastases [10, 14]. In one series of
metastatic gastrointestinal NET, ALP ≥ upper limit of normal
(ULN) was associated with a median progression-free surviv-
al (PFS) of 10 months versus 33 months with normal ALP
(multivariate HR, 2.49, P= 0.017) [10].
Tumour size is often considered a prognostic factor for
patients treated with radiolabelled somatostatin analogue
(SSA) [15]. Lutetium-177 (177Lu) is a beta- and gamma-
emitting radionuclide [16]. Compared with Yttrium-90
(90Y), 177Lu has lower maximum and mean beta particle
energies and maximum and mean soft-tissue penetration
depths of 1.7 and 0.23 mm, respectively [16], considered
ideal for treatment of intermediate-sized tumours but
hypothesised to be suboptimal for large tumours [15, 17,
18]. However, correlation between tumour size and 177Lu
effectiveness has not been evaluated in a randomised con-
trolled trial.
To assess the impact of these potential prognostic and pre-
dictive factors on 177Lu-Dotatate efficacy and toxicity, we
conducted a post hoc analysis of the NETTER-1 trial, the only
prospective phase 3 study of a radiolabelled SSA [19]. In
NETTER-1, 231 patients with progressive midgut NET were
randomised to 177Lu-Dotatate every 8 weeks for four cycles,
or high-dose octreotide LAR 60 mg every 4 weeks. At the
time of primary endpoint data analysis (24 July 2015), median
PFS was not reached (NR) in the 177Lu-Dotatate arm and was
8.4 months in the control arm (HR 0.21; 95% CI 0.13–0.33)
[19]. Health-related QOL analysis (30 June 2016) demonstrat-
ed significant improvement in time to decline (TTD) with
177Lu-Dotatate in the clinically relevant domains of global
health status, physical functioning, role functioning, diar-
rhoea, pain, and fatigue [20].
We assessed the impact of baseline liver tumour burden on
177Lu-Dotatate treatment efficacy outcomes (PFS), TTD in
QOL, and hepatic toxicity rates. We evaluated the predictive
and prognostic power of elevated ALP, whether presence of ≥
1 target lesion >3 cm in diameter impacted PFS benefit with
177Lu-Dotatate, and whether baseline tumour size correlated
inversely with tumour shrinkage rates.
Methods
NETTER-1 key eligibility criteria and study design
Eligible patients were aged ≥ 18 years with locally advanced
or metastatic, low-, or intermediate-grade (Ki-67 ≤ 20%) NET
originating in the midgut with radiologic disease progression
(according to Response Evaluation Criteria in Solid Tumours
version 1.1 over ≤3 years) while receiving a standard dose of
octreotide. All target lesions were required to be somatostatin-
receptor-positive. Hepatic exclusion criteria were total biliru-
bin > 3× ULN and serum albumin ≤ 3.0 g/dL, unless pro-
thrombin time was within normal range.
Patients were randomised to four cycles of 177Lu-Dotatate
(administered every 8 weeks) along with intramuscular (IM)
octreotide LAR 30 mg every 8 weeks (followed by mainte-
nance octreotide LAR 30 mg every 4 weeks) or to high-dose
octreotide LAR 60 mg every 4 weeks. Patients were stratified
by highest tumour uptake on somatostatin receptor scintigra-
phy and by duration of prior treatment with constant-dose
octreotide LAR (≤ 6 or > 6 months).
The trial protocol was approved by the institutional review
board or independent ethics committee at each institution. The
trial was performed in accordance with the principles of the
Declaration of Helsinki, International Conference on
Harmonisation Good Clinical Practice guidelines, and all ap-
plicable regulations. All patients provided written informed
consent.
PFS by extent of liver tumour burden
Baseline liver tumour burdenwas estimated by blinded central
radiology review (Keosys, Saint Herblain, France) and
categorised into subgroups of low (< 25%), moderate (25–
50%), or high (> 50%) tumour burden according to liver tu-
mour volume divided by total liver volume by computed to-
mography (CT) or magnetic resonance imaging (MRI). The
thresholds chosen were similar to those described in prior
phase 3 studies evaluating SSAs in NETs [2, 21].
PFS curves for each treatment arm and median PFS with
corresponding 95% CIs were generated using Kaplan-Meier
estimates, stratified by liver tumour burden, and the log-rank
test was used for within–treatment arm comparisons of PFS.
HRs with corresponding 95%CIs and P-values were estimated
using a Cox regression model with randomised treatment, liver
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tumour burden at baseline and liver tumour burden ×
randomised treatment interaction term as covariates. The pri-
mary data analysis cutoff was 24 July 2015.
PFS by baseline ALP
PFS curves were generated for each treatment arm, stratified
by baseline ALP (normal, or > ULN, based on institutional
ULN), and the log-rank test was used for within–treatment
arm PFS comparisons. HRs with corresponding 95% CIs
and P-values were generated using the methodology de-
scribed above.
PFS by presence or absence of a large lesion
Patients were stratified into two subgroups based on the pres-
ence or absence of at least one target lesion >30 mm in diam-
eter at any body site on CT or MRI at baseline. This approx-
imate size threshold has been described in previous literature
as distinguishing ‘large’ tumours from smaller ones in animal
studies of peptide receptor radionuclide therapy (PRRT) [18,
22]. PFS curves were generated for each treatment arm, strat-
ified by the presence or absence of large target tumour, and the
log-rank test was used for within–treatment arm comparisons
of PFS. HRs with corresponding 95% CIs and P-values were
generated using the methodology described above.
Liver lesion shrinkage by baseline liver lesion size
A mixed model repeated measures (MMRM) analysis includ-
ed study visit, baseline tumour size (≤ 30 mm and > 30 mm),
and baseline tumour size × study visit interaction as fixed
effects, and was used to evaluate the effect of baseline tumour
size on least squares mean percentage change in tumour size
from baseline to week 72 (data cutoff, 30 June 2016).
Hepatic toxicity by extent of liver tumour burden
Assessment of grade 3 or 4 liver function test (LFT) abnor-
malities (aspartate aminotransferase [AST], alanine amino-
transferase [ALT], ALP, albumin, and bilirubin) was stratified
by tumour burden categories described above. The analysis
comprised all patients who underwent randomisation and re-
ceived at least one dose of trial treatment (data cutoff, 30
June 2016). Adverse events in NETTER-1 were graded ac-
cording to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.02.
QOL by extent of liver tumour burden
TTD of QOL (data cutoff, 30 June 2016) was defined as the
time from randomisation to first deterioration ≥ 10 points
(100-point scale) compared with baseline on EORTC QLQ-
C30 and GI-NET21. TTD was estimated using Kaplan-Meier
methodology and stratified by liver tumour burden subgroup:
low (< 25%) or moderate to high (≥ 25%).
Results
In total, 231 patients (117 177Lu-Dotatate patients, 114 high-
dose octreotide patients) were enrolled in NETTER-1; 223
received at least one dose of study drug and were eligible for
safety analysis (see Fig. S1 in the Supplementary material). At
the time of the primary PFS analysis, 229 patients were en-
rolled. Most had liver metastases at baseline (98/116 [84.5%]
and 94/113 [83.2%] in the 177Lu-Dotatate and octreotide arms,
respectively). Supplementary Table S1 summarizes the dis-
tribution of patients stratified by liver tumour burden, ALP
elevation, and presence of a large target lesion at baseline.
PFS by extent of liver tumour burden
Statistically and clinically significant prolongation of PFS
with 177Lu-Dotatate was observed in patients with low, mod-
erate, and high liver tumour burden, with nearly identical HRs
for progression or death across all prognostic groups (Fig. 1).
Median PFS was NR in the 177Lu-Dotatate arm versus
9.1 months in the high-dose octreotide arm (HR 0.19;
P < 0.0001) in those with low burden; NR versus 8.7 months
in those with moderate burden (HR 0.22; P= 0.0098); and
NR versus 5.4 months in those with high burden (HR 0.15;
P= 0.0018).
Within the 177Lu-Dotatate arm, no significant difference in
PFS was observed with low, moderate, or high baseline tu-
mour burden (log-rank P = 0.7225). However, within the
high-dose octreotide arm, there was a significant correlation
between liver tumour burden and PFS, with median PFS of
9.1, 8.7, and 5.4 months for low, moderate, and high burdens,
respectively (log-rank P = 0.0169).
PFS by normal or elevated ALP
In each treatment arm, 112 patients had evaluable baseline
ALP. Statistically and clinically significant prolongation of
PFS with 177Lu-Dotatate was observed amongst patients with
normal and elevated baseline ALP, with nearly identical HRs
for progression or death in both prognostic groups (Fig. 2), as
reported in the original subgroup analysis of the NETTER-1
study [19]. Median PFS was NR in the 177Lu-Dotatate arm
versus 8.5 months in the high-dose octreotide arm (HR 0.15;
P < 0.0001) in the normal ALP group and NR versus
5.8 months (HR 0.18; P < 0.0001) in the elevated baseline
ALP group.
No significant difference in PFS was observed amongst
patients with normal versus elevated ALP in the 177Lu-
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Dotatate (log-rank P = 0.3532) or high-dose octreotide arm
(log-rank P = 0.0911).
PFS by presence of a large target lesion
Amongst target lesions in patients within the 177Lu-Dotatate
arm, 128 large tumours (>30 mm diameter) were identified, of
which 89 (70%) were liver tumours; in the high-dose
octreotide arm, 134 large tumours were identified; 93 (69%)
were liver tumours. Regardless of presence or absence of a
large baseline lesion, median PFS was significantly prolonged
amongst patients treated with 177Lu-Dotatate versus high-dose
octreotide (Fig. 3). The benefit was particularly pronounced
amongst patients with no large target baseline lesion: median
PFS was NR in the 177Lu-Dotatate arm versus 8.3 months in
the high-dose octreotide arm (HR 0.063; P = 0.0002).
However, there was also clinically and statistically significant
benefit of 177Lu-Dotatate amongst patients with ≥ 1 large tar-
get tumour; median PFS was NR in the 177Lu-Dotatate arm
versus 8.5 months in the high-dose octreotide arm (HR 0.21;
P < 0.0001).
The presence or absence of a large baseline lesion did not
impact the PFS of patients receiving high-dose octreotide (me-
dian PFS, 8.5 versus 8.3 months; log-rank P = 0.3566).
However, absence of a large target lesion was associated with
improved PFS in the 177Lu-Dotatate arm (log-rank
P= 0.0222), although median PFS was NR in both groups.
Decrease in target liver tumour diameter stratified
by baseline liver tumour size
To assess whether baseline liver tumour size correlates with
radiographic tumour shrinkage in patients receiving 177Lu-
Dotatate, we stratified target lesions into two groups based
Low (<25%)
liver tumour burden 
Moderate (25–50%)
liver tumour burden 
High (>50%)
liver tumour burden 
177Lu-Dotatate +
octreotide LAR 30 mg 
177Lu-Dotatate +
octreotide LAR 30 mg 
177Lu-Dotatate +
octreotide LAR 30 mg 
71 62 53 41 29 22 14 10 6 3 0
Octreotide LAR 60 mg 70 55 35 21 14 10 4 3 1 0 0
26 23 16 12 9 7 3 1 0 0 0
Octreotide LAR 60 mg 13 8 5 2 1 1 0 0 0 0 0
19 15 11 8 5 5 3 2 0 0 0
Octreotide LAR 60 mg 30 18 10 7 3 0 0 0 0 0 0
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Baseline liver
tumour burden Treatment arm n Events, n (%) Median PFS, months HR (95% CI) P
Low (<25%)
177Lu-Dotatate + octreotide LAR 30 mg
177Lu-Dotatate + octreotide LAR 30 mg
177Lu-Dotatate + octreotide LAR 30 mg
Low versus moderate versus high, P = 0.7225 
177Lu-Dotatate + octreotide LAR 30 mg
71 12 (16.9) NR 0.187 
(0.098–0.359)
<0.0001
Octreotide LAR 60 mg 70 40 (57.1) 9.10
Moderate (25–50%)
26 5 (19.2) NR 0.216 
(0.067–0.691)
0.0098
Octreotide LAR 60 mg 13 7 (53.8) 8.74
High (>50%)
19 4 (21.1) NR 0.145 
(0.043–0.486)
0.0018
Octreotide LAR 60 mg 30 23 (76.7) 5.42
Octreotide LAR 60 mg
Low versus moderate versus high, P = 0.0169
Fig. 1 Kaplan-Meier analysis of progression-free survival by treatment
arm (patients randomised to four cycles of peptide receptor radionuclide
therapy with 177Lu-Dotatate + octreotide LAR 30 mg or octreotide LAR
60 mg) and baseline extent of liver tumour burden (low [< 25%],
moderate [25–50%], or high [> 50%]). Liver tumour burden is
calculated according to liver tumour volume divided by total liver
volume by computed tomography or magnetic resonance imaging. Data
cutoff: 24 July 2015. HRs with corresponding 95% CIs and P-values
were estimated using a Cox regression model with randomised
treatment, liver tumour burden at baseline, and liver tumour burden ×
randomised treatment interaction term as covariates. Log-rank test used
for within-treatment arm comparisons of PFS. CI: confidence interval,
HR: hazard ratio, LAR: long-acting release, NR: not reached, PFS:
progression-free survival
Eur J Nucl Med Mol Imaging
on tumour diameter: ≤ 30 mm and > 30 mm. Changes in mea-
surements at each scanning interval up to 72 weeks were eval-
uated for each lesion and averaged for each baseline size cat-
egory (Fig. 4). Tumour size significantly decreased from base-
line to week 72 (P < 0.0001) regardless of baseline size. At
72 weeks, least squares mean shrinkage was 29% and 14% in
the ≤ 30 mm and > 30 mm groups, respectively. There was a
significant interaction of baseline tumour size by time of visit
(P = 0.0085) within the 177Lu-Dotatate-treated group, indicat-
ing that liver tumour size shrinkage over time differs by base-
line size.
TTD in QOL stratified by baseline liver tumour burden
In patients with low tumour burden (< 25%), median TTD of
global health status was 28.8 months in the 177Lu-Dotatate
arm versus 6.1 months in the high-dose octreotide arm (HR
0.376; P = 0.0022). In patients with moderate/high tumour
burden (≥ 25%), the median TTD of global health status was
NR in the 177Lu-Dotatate versus 6.0 months in the high-dose
octreotide arm (HR 0.45; P= 0.0868). The median TTD of
other clinically relevant QOL domains stratified by tumour
burden are shown in Supplementary Table S2.
Analysis of hepatic toxicity by extent of baseline liver
tumour burden
Grade 3 and 4 LFTabnormalities were rare and did not appear
to be associated with high baseline liver tumour burden in
either arm (Table 1). Because of the very low frequency of
clinically significant toxicity in both arms, a comparative sta-
tistical test was not performed.
Discussion
The impact of liver tumour burden and largest tumour size on
outcomes with 177Lu-Dotatate has not been well established,
ALP ≤ ULN
ALP > ULN
177Lu-Dotatate +
octreotide LAR 30 mg 
71 63 51 40 29 25 14 7 4 2 0
Octreotide LAR 60 mg
177Lu-Dotatate +
octreotide LAR 30 mg 
Octreotide LAR 60 mg
75 57 36 21 13 8 3 3 1 0 0
41 33 26 20 13 9 6 6 2 1 0
37 23 13 8 4 2 0 0 0 0 0
Participants at risk:
ALP ≤ ULN
177Lu-Dotatate + octreotide LAR 30 mg
177Lu-Dotatate + octreotide LAR 30 mg
177Lu-Dotatate + octreotide LAR 30 mg
Normal versus elevated, P = 0.3532 
71 11 (15.5) NR 0.153 
(0.078–0.298)
<0.0001
Octreotide LAR 60 mg 75 44 (58.7) 8.54
ALP > ULN
41 8 (19.5) NR 0.177 
(0.079–0.398)
<0.0001
Octreotide LAR 60 mg 37 25 (67.6) 5.78
Octreotide LAR 60 mg
Normal versus elevated, P = 0.0911
Baseline ALP Treatment arm n Events, n (%) Median PFS, months HR (95% CI) P
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Fig. 2 Kaplan-Meier analysis of progression-free survival by treatment
arm (patients randomised to four cycles of peptide receptor radionuclide
therapy with 177Lu-Dotatate + octreotide LAR 30 mg or octreotide LAR
60 mg) and baseline normal (≤ULN) or elevated (> ULN) alkaline
phosphatase levels (based on institutional ULN). Data cutoff: 24
July 2015. One-hundred twelve patients in either treatment arm had
evaluable baseline ALP levels and were included in this analysis. HRs
with corresponding 95% CIs and P-values were estimated using a Cox
regression model with randomised treatment, alkaline phosphatase level,
and alkaline phosphatase level × randomised treatment interaction term as
covariates. Log-rank test was used for within-treatment arm comparisons
of PFS. ALP: alkaline phosphatase, CI: confidence interval, HR: hazard
ratio, LAR: long-acting release, NR: not reached, PFS: progression-free
survival, ULN: upper limit of normal
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partly owing to lack of randomised studies, which are often
necessary to identify predictive factors. Two retrospective
studies of 177Lu-Dotatate have demonstrated that tumour
burden ≥ 25% is associated with a shorter median OS in mul-
tivariate analyses (HR 2.9 and 2.1, respectively); however, the
relationship with PFS was not investigated [5, 6]. Our analysis
37 32 28 17 16 12 6 4 4 3 0
39 30 16 9 6 4 3 3 1 0 0
79 68 52 44 27 22 14 9 2 0 0
74 51 34 21 12 7 1 0 0 0 0
Participants at risk:
No large lesion
177Lu-Dotatate + octreotide LAR 30 mg
177Lu-Dotatate + octreotide LAR 30 mg
37 2 (5.4) NR 0.063
(0.015–0.273)
0.0002
Octreotide LAR 60 mg 39 21 (53.8) 8.31
≥1 large lesion
79 19 (24.1) NR 0.213 
(0.124–0.366)
<0.0001
Octreotide LAR 60 mg 74 49 (66.2) 8.54
No large
lesion
≥1 large
lesion
Baseline large
lesions
Treatment arm n Events, n (%) Median PFS, months HR (95% CI) P
177Lu-Dotatate +
octreotide LAR 30 mg 
Octreotide LAR 60 mg
177Lu-Dotatate +
octreotide LAR 30 mg 
Octreotide LAR 60 mg
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Fig. 3 Kaplan-Meier analysis of progression-free survival by treatment
arm (patients randomised to four cycles of peptide receptor radionuclide
therapy with 177Lu-Dotatate + octreotide LAR 30 mg or octreotide LAR
60 mg) and presence or absence of at least one large (> 30 mm diameter)
target lesion at any site of the body at baseline imaging with computed
tomography or magnetic resonance imaging. Data cutoff: 24 July 2015.
HRs with corresponding 95% CIs and P-values were estimated using a
Cox regression model with randomised treatment, presence/absence of
large target lesion, and presence/absence of large target lesion ×
randomised treatment interaction term as covariates. Log-rank test was
used for within–treatment arm comparisons of PFS. CI: confidence
interval, HR: hazard ratio, LAR: long-acting release, NR: not reached,
PFS: progression-free survival
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Fig. 4 Least squares mean
percentage change from baseline
in the size of liver lesions at each
study visit in the 177Lu-Dotatate
arm, stratified by baseline liver
lesion size. Data cutoff: 30
June 2016. A lesion-based mixed
model repeated measures analysis
included study visit, baseline
target liver lesion size (≤ 30 mm
or > 30 mm), and baseline target
liver lesion size × study visit
interaction as fixed effects
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demonstrates that high tumour burden does not predict dimin-
ished PFS benefit from 177Lu-Dotatate versus high-dose
octreotide. Indeed, the HR for PFS benefit in the high tumour
burden group was nearly identical to the benefit in the low
burden cohort. When evaluating each treatment arm separate-
ly, high tumour burden was a negative prognostic factor for
PFS in the high-dose octreotide arm but did not correlate with
negative outcomes in the 177Lu-Dotatate arm, suggesting that
177Lu-Dotatate may mitigate the negative impact of tumour
burden.
Similar findings were observed with ALP elevation as with
tumour burden, which is consistent with the association of
ALP with tumour burden [10]. The HR for PFS benefit with
177Lu-Dotatate versus high-dose octreotide in the high ALP
group was nearly identical to the benefit in the normal ALP
group. A study of patients treated with 177Lu-Dotatate has
demonstrated ALP elevation (> 120 IU/L) to be a negative
prognostic factor in terms of OS, but did not assess PFS [9].
In this study, presence or absence of a large (> 30mm) target
lesion did not impact the PFS of patients receiving high-dose
octreotide (median PFS 8.3 versus 8.5 months, respectively).
This suggests that the effect of octreotide is independent of
tumour size. Patients lacking a large target lesion had a partic-
ularly pronounced PFS benefit with 177Lu-Dotatate versus
high-dose octreotide, with a 94% improvement in risk of pro-
gression or death (HR 0.06). PFS benefit with 177Lu-Dotatate
versus high-dose octreotide was also seenwith at least one large
target lesion (HR 0.21). However, in those receiving 177Lu-
Dotatate, absence of a large target lesion was associated with
improved PFS. Mean tumour shrinkage with 177Lu-Dotatate
correlated with baseline tumour size, being highest in target
lesions ≤ 30 mm. These outcomes indicate the effectiveness
of 177Lu-Dotatate across a spectrum of tumour sizes but also
suggest that its effectiveness is particularly high in smaller tu-
mours. Randomized trials are necessary to prove or disprove
the hypothesis that longer-range radionuclides (e.g, 90Y) should
be used in combination or as an alternative to 177Lu-based
PRRT in patients with large tumours.
The QOL findings suggest that 177Lu-Dotatate has a clini-
cally relevant beneficial impact on overall QOL as well as on
specific NET-related symptoms regardless of tumour burden.
However, when stratified by tumour burden, most QOL re-
sults were not significant owing to the small number of pa-
tients in each cohort (data not shown).
Concerns exist regarding the safety of 177Lu-Dotatate in
patients with high tumour burden owing to the potential for
radiation hepatitis. Data from NETTER-1 did not validate this
hypothesis. LFT elevations were rare and did not appear to
correlate with baseline tumour burden. It is important to note,
however, that safety findings in patients with tumour burden
> 50% do not necessarily imply that treatment is equally safe
in patients with extreme tumour burden (e.g., > 90%). A lim-
itation of this study is that central readers did not specify the
patients with extreme tumour burden (> 90%), and therefore
no specific safety analysis in that subgroup was possible.
In summary, 177Lu-Dotatate demonstrated significant prolon-
gation in PFS versus high-dose octreotide in patients with ad-
vanced, progressive midgut NET, regardless of baseline liver
tumour burden, elevated ALP, or presence of a large target le-
sion. 177Lu-Dotatate is effective across a spectrum of tumour
sizes, but its effectiveness is particularly high in smaller tumours,
potentially supporting early treatment in patients with progres-
sive disease. Clinically relevant LFTabnormalities were rare and
were not associated with high baseline liver tumour burden.
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ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, LAR: long-acting release
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